Belgium: Punching Well Above its Weight in Clinical Trials
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Address: Namur Office Park
Avenue des dessus de Lives, 6
5101 NAMUR-LOYERS,Belgium
Tel: +32(0)81/33.28.50
Web: http://www.investinwallonia.be/?lang=en
Wallonia’s economy is very focused on the global market and it is one of the largest exporters per capital worldwide.
To support the establishment of prospective foreign investors, the Wallonia government set up a specially trained team in the late 1990s with the objective of assisting all foreign investors in the implementation of their investment project in Wallonia.
This team is called the Office for Foreign Investors (O.F.I) and it forms part of the Agence Wallonne à l’Exportation et aux Investissements étrangers (Wallonia agency for exports and foreign investment).
With the support of public and private players, O.F.I. assists at all stages in successfully establishing businesses in Wallonia by providing invaluable advice in the following spheres: choice of location, grant schemes, tax regime, recruitment and training of staff, project financing arrangements.
Grant schemes, Tax regime, Recruitment and Training of staff, Project financing
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare regulatory framework since being founded in 2007. De…
Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt…
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on…
Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home…
Teun Grooters, co-founder and CEO of Arega – the exclusive distributor of Teva generics in Belgium – tells the story of the newly founded pharmaceutical company and shares his future…
Belgian Former Minister of Social Affairs, Public Health and Asylum & Migration Maggie de Block outlines some of the key reforms her Ministry has rolled out since she took office…
Frank Swaelens, general manager of IQVIA in Belgium and Luxembourg, offers insights into the healthcare and life science ecosystem of Belgium and highlights the opportunities that exist for the country…
Françoise Smets, dean of the Faculty of Medicine and Dentistry at Université Catholique de Louvain (UCLouvain), introduces the innovation and research capacity of the institution as the top-ranking French-speaking university…
Teva Pharma Belgium’s Eric Deschepper outlines how the global group’s restructuring has impacted its Belgian operations, its realignment from a pure generics to a specialty pharma player, and how the…
Over the past few decades, pharma multinationals have been increasingly drawn to the highly cost-competitive markets of Central Eastern Europe (CEE) and Asia to situate major manufacturing sites. However, despite…
See our Cookie Privacy Policy Here
